Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
This from the disciple who would never have bought NWBO shares back in 2014 despite LP saying everything was going swimmingly and maybe missing out on an acquisition, instead finding that sweet 15 cents spot after now legacy shareholders were destroyed.
Like I said, the company needs to be acquired quickly based on inside knowledge the data looks really promising, or it's over current shareholders.
>>Those in the placebo arm received chambers with an inactive solution.
>>Progression-free survival (PFS) is the trial’s primary endpoint while overall survival (OS) and safety will be assessed as key secondary endpoints.
Top-line data from the trial is anticipated to be released by mid-2025.
>>Imvax also secured approximately $35m in a funding round, and half of the investment came from new investors.
To support the completion of the Phase IIb trial of IGV-001, the company secured $57m over the past 15 months.
Imvax CEO John Furey said: We are also delighted that the FDA has granted fast track designation to IGV-001.
“The last significant advancement in the standard of care for GBM – about an eight-week improvement in PFS – was nearly 20 years ago, highlighting the need for continued innovation and treatment options.
https://www.clinicaltrialsarena.com/news/imvax-glioblastoma-treatment-trial/?cf-view
DCVAX-L was not used for Pl or Pll, of course. It was only introduced during the Plll.
“We tested the method with a single patient in 1997, and then moved to a phase 1 safety trial in the early 2000s,” says Dr. Liau, professor and chair of Neurosurgery at UCLA.
A series of phase 2 early efficacy and optimization trials followed, and then an international, multi-site study led by Dr. Liau began in 2007.
The vaccine consists of two components: a patient’s dendritic cells, which are special types of immune cells, and proteins prepared from a patient’s tumor.
To create the vaccine, which is individualized for each patient, medical staff first perform a procedure called leukapheresis, in which a patient’s blood is drawn and their white blood cells are collected. Then, the patient’s tumor is removed and sent to a lab where researchers obtain proteins from the specimen, called tumor lysate. The white blood cells are cultured to differentiate into dendritic cells, and then combined with the tumor lysate to make the vaccine.
Small "tweaks" in the process that provide NWBO with patent protection have made L different from UCLA's DC version. Now, you can ask if over time UCLA has slowly come to rely on NWBO/Advent for DCVAX-L instead of producing it on their own for their clinical trials, but you can't just say the two are the same without a real explanation from the company.
Just because a company can hire some other company skilled in an area doesn't allow them to forgo that specific risk factor. The ultimate risk factor with this one is total lack of experience bringing a drug to market. That won't go away no matter how many 10q's you read.
Les said the fall. Oh, and also mentioned he had 50k retail investors.
>>The fact is, nobody, except the company, knows when the clock actually started
Just look at Geron and throw everything you just said out the window! There's plenty that they can do while they wait.
What's the lie?
Add to it the messy Pl and ll, as per that article I posted. Investors never saw a PR acknowledging any regulators green lighted the Plll change. About the only positive is that MHRA approved a similar PIP trial using EC. However, there seems to be no interest in running that trial so far.
>>Form 10-K requires disclosures of risk factors under Item 105, but Form 10-Q also requires disclosure of any material changes since the last Form 10-K (for all companies other than smaller reporting companies).
Ahahaha!!!
You'll recall about a week ago I mentioned the odd UCLA Pll that somehow morphed into a NWBO Plll. Learn from the history.
>>However, a key element of Trial #2 is that most patients received additional treatment of a TLR agonist (either Imiquimod or Poly-ICLC) in conjunction with DCVax-L.
https://seekingalpha.com/article/2534085-northwest-biotherapeutics-misrepresents-clinical-trial-data
With what cash or does she intend to take it all private?
So your partner, DocLogic, wrote that but you replied. Either way neither of you came back with clarification. That's because management admitted nothing of the kind. Just more fibs by the disciples.
Still waiting to hear back from you on your fib, SkyLimit.
Enlighten us please.
>>and they have admitted to certain things that they could have done better.
Having a faulty memory on something politics related has nothing to do with my very accurate postings on this board, as hard as you may try to prove otherwise.
Btw, you're allowing AI to melt your brains instead of doing the homework and writing yourselves.
LOL. Set up just like a patent troll with a UK facility for rent.
That's right, I forgot, the $450M was so absurd it had to be adjusted down. Nobody would ever insure that amount. Still a ton of money at his disposal and changes nothing I said about the grifter vs. the businessman.
I simply asked you to clarify your statement but you couldn't. Instead the misguided threats.
>>It sounds to me as if you’re attempting to defame certain individuals or spread rumors,
Legacy shareholders are down 99.x % over fifteen years. LP is up tens of millions.
>>keeping the value of this platform technology 100% in the hands of investors
Enlighten us please.
>>and they have admitted to certain things that they could have done better.
Yes, and that's exactly when a BP should step in to buy a small biotech for a handsome premium making the acquirer and common very happy. Never happened, of course, and LP was just full of nonsense.
>>No cult. I just recognize the reality. And I would not have invested much 12 years ago because honestly, I’ve known enough bios to know that they had a long way to go. I was watching them then.
So, 13 years ago LP says they're good to go with cost issues and profitability with a vaccine showing good results and practically no side effects. Since then the company has lost its retail shareholders 99% plus of their investment and gone into hiding. BioHarm says management is doing a great job. LOL
Nonsense?!!! LOL. It's their own false words...their own history. What you fail to recognize is that with NWBO it's all the crew! No management shakeups ever except for those who disappeared, of course.
https://www.linkedin.com/in/anthony-maida-9b159b247
So from lab to FDA approval of a drug with some serious side effects takes 11 years. Makes sense. DC's started in the early 90's.
Correct call from 2014.
>>The DCVax PIM designation will prove to be as meaningless as the German "hospital exemption" announced in March.
Correct:
>>The buyers of Northwest's convertible notes want the company's stock price to decline before Feb. 15, 2015, because a lower stock price will also drop the conversion price of the debt when it resets. A lower conversion price means note holders get more and cheaper Northwest shares to sell when they convert the notes. The Northwest debt holders also make extra money by shorting the stock and covering lower.
>>And Northwest will be happy to make its convertible notes more profitable for current holders at the expense of equity shareholders because when the company needs to raise cash again next year (and Northwest will definitely raise more money next year) it will find a receptive audience. Vulture investors love distressed companies who make it easy to book profits.
https://www.thestreet.com/investing/northwest-bios-almost-toxic-debt-raise-responsible-for-stock-slide-12885672
2011.
>>DCVax® immune therapies for a broad range of cancers (including prostate, brain, ovarian and others) hold the promise, based on available data to date, of being cost effective and priced below other immune therapies while still providing substantial profit margins for the Company and longer survival for patients.
https://www.biospace.com/article/releases/northwest-biotherapeutics-highlights-cost-effectiveness-of-dcvax-in-view-of-recent-immunotherapy-pricing-concerns-408411/
2011.
>>Linda Powers, CEO of NORTHWEST BIO, commented that "It is gratifying to see that the expanded management team put in place in June is moving the GBM clinical trial forward at an accelerating rate, while taking important steps toward strengthening our investor and media outreach."
https://www.fiercebiotech.com/biotech/northwest-bio-announces-positive-third-quarter-progress
Remarkable how you guys just refuse to get it. What else have they accomplished in a decade?
>>And sure hope that they didn’t take half a decade from data lock to just prepare an application and submit and wait for the decision to just one RA
They're a disaster. Zero energy coming from this company. It feels empty. Without a quick buyout this thing is toast, IMO.
I might need to change my mind on chemo soon.
https://neurosciencenews.com/glioblastoma-cancer-pathway-26147/
And speaking of loons, I see DanishDancer chimed in with another whopper.
"If fudders beg for governance and for retailers getting informed, you can rest asssured they want that in order to be able to manipulate the share price.
Its the essence of logic and reason. "
With each sentence everyone can see now that you're a loon but this one really stands out.
>>Linda Powers, the intelligent woman that she is, has been the shorts absolute worst enemy.
You could've shortened this one up to Management is executing retail.
Keep it simple. Les keeps it down whenever he does BBS appearance telling the Street they have no buyers. To make matters even worse this time he told shorts he's got 50k retail shareholders and to expect to hear from the MHRA in the fall.
Well, you at least have this part right. They've kept the company hanging on by a thread forever assuring no real analyst coverage or Street interest, just a bunch of sappy powerless retail shareholders so LP can continue do her private work without interference.
I know it's difficult, disciples, but you can do it!
Apologies for posting here about GBM patients and therapies. Wrong board.
Faith no more! Theralink going dark. Great work Faith, Mick and especially Big Al. That's quite a track record you've made for yourself. LOL
FORM 15
CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Approximate number of holders of record as of the certification or notice date: 237.
Shrugs.